Epione

French medical robotics company developing the Epione robotic platform for CT-guided percutaneous tumor ablation, enabling minimally invasive treatment of abdominal, lung, and bone cancers. Founded in 2017 by a team of former Medtech SA engineers led by Bertin Nahum, the company is headquartered in Montpellier with a US subsidiary in Miami. Now part of Precision IO Group after acquiring NeuWave Medical in February 2026, with over 1,400 patients treated across Europe and the United States.

Yes. Epione is independently verified in real-world operation on the DEPLOY registry, confirmed at named deployment sites with primary sources: not a concept, render, or demo-only.

Not verified as fully autonomous. Epione's capabilities on the DEPLOY registry are recorded as teleoperated-assisted, demonstrated-only, or vendor claims (percutaneous needle insertion for tumor ablation), not independently confirmed to run without a human in the loop.

Epione is made by Quantum Surgical, based in Montpellier, France, founded in 2017.

6 verified deployments of Epione are on the DEPLOY registry, including at Leeds, UK, London, Chicago.

Epione is in commercial deployment and is sold to operators; contact the manufacturer to buy, and see the pricing section for any recorded price.

Epione has 1 regulatory record on the DEPLOY registry: FDA 510(k) clearance, cleared. See the Regulatory filings section for each agency source.

On the DEPLOY registry, comparable surgical robots to Epione include da Vinci (and Ion), Edge Multi-Port Surgical Robot, Edison Histotripsy System, Stryker Mako SmartRobotics.

Epione and da Vinci (and Ion) (Intuitive Surgical · 15 deployments) are both surgical robots on the DEPLOY registry. Epione has 6 verified deployments on record. Compare both records for specs, safety, deployments, and verified-vs-claimed autonomy.

On DEPLOY's intelligence score, which blends verified deployments, safety, adoption, media, and IP signals, Epione ranks in roughly the top 27% of surgical models tracked by the registry.

Epione is at the commercial stage on the DEPLOY maturity ladder (research, prototype, pilot, commercial, production). Commercial stage means production-grade deployments are operating at named customer sites.

Epione has 4 active incidents on record in the DEPLOY registry. 1 recall and 3 incidents on record (1 critical, 1 moderate, 2 minor). Most recent: Mar 2026. Retracted incidents are excluded from this count.

The Epione is an interventional oncology robot by Quantum Surgical that received FDA 510(k) clearance for commercial sale and use in treating early-stage liver cancer. The FDA later cleared Epione for all abdominal cancers. Epione enables precise, image-guided percutaneous ablation of tumors.